2CB84056-3B7C-4E12-9403-596B76CCF96B
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 3.679369250985545
- age_years
- 31
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.481
- NOTCH_SIGNALING+0.479
- MITOTIC_SPINDLE+0.372
- TGF_BETA_SIGNALING+0.363
- MYC_TARGETS_V2+0.361
- DNA_REPAIR+0.308
- HEDGEHOG_SIGNALING+0.229
- G2M_CHECKPOINT+0.200
- MYC_TARGETS_V1+0.193
- ADIPOGENESIS+0.165
Top 10 suppressed
- KRAS_SIGNALING_DN-0.394
- PANCREAS_BETA_CELLS-0.385
- SPERMATOGENESIS-0.362
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.284
- INFLAMMATORY_RESPONSE-0.237
- UV_RESPONSE_UP-0.205
- ESTROGEN_RESPONSE_LATE-0.182
- ALLOGRAFT_REJECTION-0.179
- COMPLEMENT-0.169
- MYOGENESIS-0.159
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 087D4EB4-61AB-4EF4-9C76-7721E7FC5E0F | — | — | 0.892 |
| 2 | 9B4C5215-C5D9-4B2A-A8F0-74243CA8C00F | — | — | 0.884 |
| 3 | F99D2B23-A7C3-4115-AA68-17AE6914AC2A | — | — | 0.881 |
| 4 | DD028798-C4CB-43A8-81D7-711E015E23B5 | — | — | 0.879 |
| 5 | DEB3BE77-120D-4EC5-AA7A-4B2952F2C832 | — | — | 0.868 |
| 6 | 694B3BE3-104F-4D90-8733-4E99230EFAC6 | — | — | 0.866 |
| 7 | 4A4E96B0-5AC6-4B7D-AB1C-F814C338589C | — | — | 0.857 |
| 8 | 221384A6-059C-4731-9BD0-68EC9CA5651D | — | — | 0.854 |
| 9 | A1E55AC6-A41F-454A-A3B6-8F49D2AAFEF2 | — | — | 0.848 |
| 10 | 24F914FE-3DF0-4286-9231-9D525A777306 | — | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.481 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.479 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.372 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.363 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.361 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.308 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.229 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.193 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.165 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.147 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.136 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.104 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.086 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.076 | Remibrutinib | — uncovered |
| PEROXISOME | 0.067 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.051 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.027 | Inavolisib | — uncovered |